Company · MOH
Molina Healthcare Inc
Name as listed on its exchange; filed with the SEC as MOLINA HEALTHCARE, INC.
Nasdaq's symbol directory lists MOH on the New York Stock Exchange as “Molina Healthcare Inc Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 6 occasions ($5.7M); 4 planned-sale notices; 7 filings by holders of 5% or more; 3 congressional trade disclosures; 3 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Jeff D. Barlow, Chief Legal Officer sold $4.9M
- Dale B. Wolf sold $330K
- ORLANDO STEVEN J sold $160K
- Schapiro Richard M sold $159K
- HEBERT MAURICE, Chief Accounting Officer sold $115K
Every trade (6)
- SELLORLANDO STEVEN J sold $160K
- SELLDale B. Wolf sold $330K
- SELLJeff D. Barlow, Chief Legal Officer sold $1.6M
- SELLSchapiro Richard M sold $159K
- SELLHEBERT MAURICE, Chief Accounting Officer sold $115K
- SELLJeff D. Barlow, Chief Legal Officer sold $3.3M
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- Steven Orlando $147K
- THE DALE B. WOLF REVOCABLE TRUST $330K
- JEFF D BARLOW $1.6M
- Richard Shapiro $159K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- Capital World Investors 5.5%
- Vanguard Portfolio Management 4.44%
- BlackRock, Inc. 9.2%
- Giovanni Agnelli B.V. 5.21%
- AQR Capital Management, LLC 6.83%
- Capital World Investors 4.9%
- FMR LLC 3.6%
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Rohit Khanna (D-CA17): Sale $1,001 - $15,000
- Rohit Khanna (D-CA17): Purchase $1,001 - $15,000
- Rohit Khanna (D-CA17): Sale $1,001 - $15,000
Executive branch · OGE Form 278-T
Reported by the President
5 confirmed trades on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports
- Sale: MOLINA HEALTHCARE INC $1,001 – $15,000
- Sale: MOLINA HEALTHCARE INC $250,001 – $500,000
- Purchase: MOLINA HEALTHCARE INC $1,001 – $15,000
- Purchase: MOLINA HEALTHCARE INC $100,001 – $250,000
- Purchase: MOLINA HEALTHCARE INC $15,001 – $50,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Regulation FD disclosure Nov 6, 2026
- Results of operations and financial condition Oct 21, 2026
- Results of operations and financial condition Jul 22, 2026
Lobbying · Senate LDA reports
Lobbying filed
3 quarterly lobbying reports for 2026 naming Molina Healthcare Inc as the client: 1 filed by the company itself, 2 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.
- The company itself $600K
- MEHLMAN CONSULTING, INC. $80K
- FORBES-TATE no amount stated
Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.